Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Different doses of nalbuphine on sevoflurane MAC during cervical dilation in hysteroscopic surgery
ChiCTR2600115970Phase 4Not yet recruiting
- Sponsor
- Guangyuan Central Hospital
- Start
- Jan 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of nalbuphine in perioperative pain (4 arms), sponsored by Guangyuan Central Hospital. Primary endpoint: Minimum alveolar concentration (MAC) of sevoflurane. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
nalbuphine
03
Conditions
perioperative pain
Beyond the preview
Go deeper on ChiCTR2600115970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600115970.